Corona Remedies Ltd press release, Q2 FY27
Corona Remedies won ANVISA (Brazil) GMP certification for its Bhayla, Ahmedabad OSD and Women's Hormone lines.
By ScoutQuest · · 1 min read
- EBITDA Q2 FY27
- 96.0 (₹ in Cr)
- PAT margin Q2 FY27
- 13.7% (vs 14.5% in Q2 FY26)
- Chronic & semi-chronic share of revenue
- 71.2% of Q2 FY27 revenue vs 67.7% in Q2 FY26
- Release
- Results press release
- Period
- Q2 FY27
_Consolidated · Q2 FY27 & FY27_
📊 EBITDA, Q2 FY27: 96.0 (₹ in Cr)
🏭 Corona Remedies has received Good Manufacturing Practice (GMP) certification from Brazil's National Health Surveillance Agency (ANVISA) for its manufacturing facility at Bhayla, Ahmedabad, covering both Oral Solid Dosage (OSD) and Women's Hormone production lines, the company says.
📉 Profit after tax margin fell to 13.7% in Q2 FY27 from 14.5% in Q2 FY26; the company attributes the decline to higher depreciation and amortisation on its newly commissioned facilities and acquired brands.
📊 Chronic and semi-chronic products contributed 71.2% of Q2 FY27 revenue against 67.7% in Q2 FY26, as per Pharmatrac MAT Sep'26 data the company cites.
Also from Corona Remedies
Corona Remedies Q2 FY27 revenue up 22.2% to INR 441.2 Cr; H1 PAT up 22.2% to INR 120.4 Cr
30 Oct 2026
Board approves unaudited Q2 and H1 results; auditors' review conclusion not modified
30 Oct 2026
Corona Remedies Ltd press release
22 Oct 2026
More numbers
- Revenue from operations, Q2 FY27441.2 (₹ in Cr)
- Revenue from operations, H1 FY27863.6 (₹ in Cr)
- Profit after tax, Q2 FY2760.3 (₹ in Cr)
- Profit after tax, H1 FY27120.4 (₹ in Cr)
- EBITDA, Q2 FY2796.0 (₹ in Cr)
- EBITDA margin, Q2 FY2721.7%
- PAT margin, Q2 FY2713.7%
- PAT margin, Q2 FY2614.5%
- Chronic + Semi Chronic revenue share, Q2 FY2771.2%
- Chronic + Semi Chronic revenue share, Q2 FY2667.7%
- Brands with annual sales over ₹100 crore4
- Brands with annual sales over ₹200 crore1
- Outperformance vs IPM, MAT Sep'261.9 times
Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.